Pfizer (PFE) Income from Continuing Operations (2009 - 2026)
Pfizer (PFE) reported Income from Continuing Operations of 2709000000.0 for Q1 2026, down 8.91% year-over-year from 2974000000.0 in Q1 2025, and up 265.18% quarter-over-quarter from 1640000000.0 in Q4 2025.
Pfizer (PFE) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Pfizer (PFE) has 18 years of Income from Continuing Operations data on file, last reported at 2709000000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 2709000000.0, down 8.91% year-over-year; the trailing twelve-month figure through Mar 2026 was 7522000000.0 (down 29.13% YoY), and the FY2025 annual result was 7786000000.0, down 3.29% from the prior year.
- Income from Continuing Operations advanced to 2709000000.0 in Q1 2026 per PFE's latest filing, from 1640000000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 9877000000.0 in Q3 2022 and troughed at 3349000000.0 in Q4 2023.
- A 5-year average of 3112933333.33 and a median of 2974000000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations plunged 127.62% in 2023, then soared 9264.52% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 8645000000.0 in 2022, then sank by 138.74% to 3349000000.0 in 2023, then surged by 233.8% to 4481000000.0 in 2024, then plunged by 136.6% to 1640000000.0 in 2025, then surged by 265.18% to 2709000000.0 in 2026.
- Business Quant data shows PFE's Income from Continuing Operations at 2709000000.0 in Q1 2026, 1640000000.0 in Q4 2025, and 3550000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 3.30 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 2.71 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 2.71 Bn |
| Dec 31, 2025 | -1.64 Bn |
| Sep 28, 2025 | 3.55 Bn |
| Jun 29, 2025 | 2.90 Bn |
| Mar 30, 2025 | 2.97 Bn |
| Sep 29, 2024 | 4.48 Bn |
| Jun 30, 2024 | 31.00 Mn |
| Mar 31, 2024 | 3.13 Bn |
| Dec 31, 2023 | -3.35 Bn |
| Oct 1, 2023 | -2.39 Bn |
| Jul 2, 2023 | 2.34 Bn |
| Apr 2, 2023 | 5.56 Bn |
| Oct 2, 2022 | 8.65 Bn |
| Jul 3, 2022 | 9.88 Bn |
| Apr 3, 2022 | 7.88 Bn |
| Oct 3, 2021 | 8.17 Bn |
| Jul 4, 2021 | 5.83 Bn |
| Apr 4, 2021 | 4.88 Bn |
| Sep 27, 2020 | 917.00 Mn |
| Jun 28, 2020 | 2.60 Bn |